Els Lierman

894 total citations
19 papers, 453 citations indexed

About

Els Lierman is a scholar working on Hematology, Rheumatology and Genetics. According to data from OpenAlex, Els Lierman has authored 19 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 10 papers in Rheumatology and 7 papers in Genetics. Recurrent topics in Els Lierman's work include Chronic Myeloid Leukemia Treatments (11 papers), Eosinophilic Disorders and Syndromes (10 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers). Els Lierman is often cited by papers focused on Chronic Myeloid Leukemia Treatments (11 papers), Eosinophilic Disorders and Syndromes (10 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers). Els Lierman collaborates with scholars based in Belgium, Austria and Poland. Els Lierman's co-authors include Jan Cools, Peter Vandenberghe, Peter Marynen, Helen Van Miegroet, Nicole Mentens, Lucienne Michaux, P. Pierre, Idoya Lahortiga, Elizabeth H. Stover and Marc Boogaerts and has published in prestigious journals such as Blood, British Journal of Haematology and Leukemia.

In The Last Decade

Els Lierman

16 papers receiving 443 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Els Lierman Belgium	10	207	191	156	154	101	19	453
Claire Curtis United Kingdom	7	217 1.0×	138 0.7×	177 1.1×	154 1.0×	84 0.8×	9	475
Leonardo Boiocchi United States	16	127 0.6×	339 1.8×	299 1.9×	163 1.1×	55 0.5×	29	610
Jean Michel Cayuela France	10	245 1.2×	481 2.5×	411 2.6×	132 0.9×	73 0.7×	12	727
Linda M. Bavisotto United States	11	126 0.6×	127 0.7×	103 0.7×	173 1.1×	94 0.9×	18	403
Ana C. Glembotsky Argentina	17	100 0.5×	552 2.9×	311 2.0×	164 1.1×	101 1.0×	31	731
Camelia Iancu‐Rubin United States	15	85 0.4×	342 1.8×	281 1.8×	292 1.9×	40 0.4×	36	655
Fabian Peisker United States	4	88 0.4×	222 1.2×	299 1.9×	228 1.5×	32 0.3×	4	445
Hideo Hyodo Japan	10	66 0.3×	297 1.6×	212 1.4×	213 1.4×	42 0.4×	17	509
D. Le United States	7	71 0.3×	192 1.0×	53 0.3×	51 0.3×	39 0.4×	10	384
T Flores Spain	9	55 0.3×	124 0.6×	112 0.7×	232 1.5×	143 1.4×	21	570

Countries citing papers authored by Els Lierman

Since Specialization

Citations

This map shows the geographic impact of Els Lierman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Els Lierman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Els Lierman more than expected).

Fields of papers citing papers by Els Lierman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Els Lierman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Els Lierman. The network helps show where Els Lierman may publish in the future.

Co-authorship network of co-authors of Els Lierman

This figure shows the co-authorship network connecting the top 25 collaborators of Els Lierman. A scholar is included among the top collaborators of Els Lierman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Els Lierman. Els Lierman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Jayne, Sandrine, Cristina López, Inga Nagel, et al.. (2024). The chromosomal translocation t (1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1 :: IRF4 fusion. British Journal of Haematology. 205(6). 2321–2326.

Vranckx, Hilde, et al.. (2021). Next generation sequencing in therapy-related myeloid neoplasms compared to de novo myeloid neoplasms. Acta Clinica Belgica. 77(3). 658–663.

Froyen, Guy, Marie Le Mercier, Els Lierman, et al.. (2019). Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel. Cancers. 11(12). 2030–2030. 30 indexed citations

Lierman, Els, et al.. (2019). External quality assessment for molecular diagnostic laboratories in Belgium: Can we improve it?. Accreditation and Quality Assurance. 25(1). 39–49. 2 indexed citations

Michaux, Lucienne, et al.. (2018). Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients. Hematology. 23(10). 785–792. 14 indexed citations

Lierman, Els, et al.. (2018). A monocentric retrospective study of 138 therapy-related myeloid neoplasms. Annals of Hematology. 97(12). 2319–2324. 10 indexed citations

Kochuyt, Anne-Marie, Barbara Dewaele, Els Lierman, et al.. (2017). Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients. Acta Clinica Belgica. 72(2). 123–129. 3 indexed citations

Billiet, Johan, Els Lierman, Timothy Devos, et al.. (2015). Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica. 100(7). 893–897. 39 indexed citations

Papadopoulos, Petros, Carlos Graux, Jan Emmerechts, et al.. (2015). MPL p.S204P Is a Recurrent Mutation in Essential Thrombocythemia. Blood. 126(23). 2837–2837.

10.

Sadovnik, Irina, Els Lierman, Barbara Peter, et al.. (2014). Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. Experimental Hematology. 42(4). 282–293.e4. 37 indexed citations

11.

Wasąg, Bartosz, Els Lierman, Mira Meeus, Jan Cools, & Peter Vandenberghe. (2011). The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11). Haematologica. 96(6). 922–926. 43 indexed citations

12.

Lierman, Els, Rikkert L. Snoeckx, Elizabeth H. Stover, et al.. (2010). Downstream effectors of FIP1L1-PDGFRA as targets for therapy in chronic eosinophilic leukemia. Haematologica. 95. 165–165. 1 indexed citations

13.

Wasąg, Bartosz, Els Lierman, Peter Meeus, Jan Cools, & Peter Vandenberghe. (2010). The Kinase Inhibitor TKI258 Is Active Against the Novel CUX1-FGFR1 Fusion Detected In a Patient with T-Lymphoblastic Leukemia/Lymphoma and t(7;8)(q22;p11). Blood. 116(21). 2715–2715. 1 indexed citations

14.

Lierman, Els, Lucienne Michaux, P. Pierre, et al.. (2009). FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib. Leukemia. 23(5). 845–851. 81 indexed citations

15.

Lierman, Els & Jan Cools. (2009). Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. Expert Review of Anticancer Therapy. 9(9). 1295–1304. 8 indexed citations

16.

Lierman, Els, et al.. (2009). Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen. Haematologica. 94(10). 1440–1444. 13 indexed citations

17.

Lierman, Els, et al.. (2008). Management of molecular resistance in a patient with fip1l1-pdgfra positive eosinophilic leukemia. Haematologica. 93. 314–314. 1 indexed citations

18.

Lierman, Els, Idoya Lahortiga, Helen Van Miegroet, et al.. (2007). The ability of sorafenib to inhibit oncogenic PDGFR and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica. 92(1). 27–34. 68 indexed citations

19.

Lierman, Els, Cedric Folens, Elizabeth H. Stover, et al.. (2006). Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant. Blood. 108(4). 1374–1376. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact